When compared to serum CEA, the sensitivity of TAC1 for detecting recurrence was higher (58.1% vs. 32.6%, P = 0.019) at 6 months postresection and was able to detect CRC clinical recurrence 2.2 months prior to CEA [13]. This evidence concerns the gene TAC1 and colorectal carcinoma.